EXOZYMES INC. 8-K

What Happened

• eXoZymes Inc. announced it completed a firm‑commitment underwritten offering with Public Ventures LLC (d/b/a MDB Capital) as sole underwriter. Under an agreement dated June 5, 2026, the company sold units of two common shares and one warrant at $18.00 per unit.
• The offering originally comprised 592,270 shares and 296,135 warrants (296,135 units). MDB had a 45‑day option to purchase up to 15% more units; on June 17, 2026 MDB exercised part of that option, buying 34,440 additional units (68,880 shares and 34,440 warrants). Inclusive of the over‑allotment, total units sold were 330,575, for gross proceeds of approximately $5.95 million before fees and expenses.
• Warrants were issued under a Warrant Agent Agreement with VStock Transfer, LLC. The offering was made under the company’s effective Form S‑3 shelf registration (declared effective Jan 23, 2026) with a final prospectus supplement filed June 8, 2026.

Key Details

• Units sold: 330,575 (each unit = 2 shares + 1 warrant).
• Shares issued: 661,150 common shares (592,270 initial + 68,880 over‑allotment).
• Warrants issued: 330,575 warrants (296,135 initial + 34,440 over‑allotment).
• Price per unit: $18.00; gross proceeds: ≈ $5.95 million (before underwriting discounts, commissions, and expenses).
• Underwriter/book‑runner: Public Ventures LLC (d/b/a MDB Capital). Warrant agent: VStock Transfer, LLC. Legal opinion: Spencer Fane LLP (filed as exhibit).

Why It Matters

• The financing provides eXoZymes with fresh capital to support development and commercialization of its lead candidate N‑trans‑caffeoyltyramine (NCT), advance other product opportunities, fund R&D, and for general corporate purposes—important for ongoing operations and pipeline progress.
• The transaction increases the company’s outstanding share and warrant counts, which can affect future dilution and capitalization; investors should factor the new shares and warrants into per‑share metrics and potential dilution from warrant exercises.